Literature DB >> 32484901

Re The source of elevated plasma D-dimer levels in COVID-19 infection.

Beverley J Hunt1, Marcel Levi2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32484901      PMCID: PMC7300986          DOI: 10.1111/bjh.16907

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


× No keyword cloud information.
Dear Sir, Markedly elevated D‐dimer levels are seen in severe Covid‐19 infection and have been related to a poor prognosis. , D‐dimers are elevated alongside other acute inflammatory plasma markers such as fibrinogen, C‐reactive protein (CRP) and serum ferritin. The elevation of plasma D‐dimers has been taken to indicate there is a coagulopathy, and the assumption has been made that the increased fibrinolysis is secondary (due to thrombin generation), indeed an indication of disseminated intravascular coagulation (DIC). However frank DIC seems unlikely as these patients do not fulfil the International Society on Thrombosis and Haemostasis (ISTH) criteria for DIC and there is hardly consumption of coagulation factors and physiological anticoagulants; indeed fibrinogen levels are very elevated. , , , We propose an alternative hypothesis: we suggest that the origin of D‐dimers is a direct consequence of the acute lung injury seen in Covid‐19 pneumonia. For one, the hallmark of acute lung injury is intra‐alveolar fibrin deposition. The levels of fibrin are controlled by alveolar epithelial cells which produce urokinase and regulate extravascular proteolysis by regulating expression of urokinase‐type plasminogen activator (uPA), its receptor uPAR, and plasminogen activator inhibitor‐1 (PAI‐1) at post‐transcriptional levels. Urokinase then converts plasminogen to plasmin, which cleaves local fibrin. Covid‐19 infection has many clinical and histological similarities to Severe Acute Respiratory Syndrome Coronoavirus (SARS‐CoV). Gralinski et al. have shown in a mouse model of SARS‐CoV a critical role for the urokinase pathway in regulating severe end‐stage lung disease outcomes following SARS‐CoV infection. They showed that the larger the dose of SARS the more severe was the clinical manifestation and greater the rise in lung urokinase expression. Lastly, another marker of Covid‐19 pneumonia is the presence of many macrophages within the lung tissue. Macrophages are well known to generate plasmin and metalloproteinases (MMPs), but they have also been described to produce fibrinolysis by an alternative pathway — fibrin and fibrinogen bind to CD11b/CD16 (also known as Mac‐1) and are internalised into lysosomes where cathepsin D can degrade fibrin and fibrinogen independently of plasmin. Based on the above evidence we suggest it is logical to consider that D‐dimer levels, like those of other acute‐phase proteins such as CRP, ferritin and fibrinogen, which are similarly very high in severe Covid‐19 infections, represent the degree of lung inflammation present within the lungs in Covid‐19 infection. Being related to the extent of lung inflammation would therefore explain why their plasma levels relate to clinical outcome .

Conflicts of interest

The authors declare to have no potential conflicts of interest regarding the present work.
  5 in total

1.  Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.

Authors:  F B Taylor; C H Toh; W K Hoots; H Wada; M Levi
Journal:  Thromb Haemost       Date:  2001-11       Impact factor: 5.249

Review 2.  The macrophage and fibrinolysis.

Authors:  J Loscalzo
Journal:  Semin Thromb Hemost       Date:  1996       Impact factor: 4.180

3.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.

Authors:  Ning Tang; Dengju Li; Xiong Wang; Ziyong Sun
Journal:  J Thromb Haemost       Date:  2020-03-13       Impact factor: 5.824

4.  Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury.

Authors:  Lisa E Gralinski; Armand Bankhead; Sophia Jeng; Vineet D Menachery; Sean Proll; Sarah E Belisle; Melissa Matzke; Bobbie-Jo M Webb-Robertson; Maria L Luna; Anil K Shukla; Martin T Ferris; Meagan Bolles; Jean Chang; Lauri Aicher; Katrina M Waters; Richard D Smith; Thomas O Metz; G Lynn Law; Michael G Katze; Shannon McWeeney; Ralph S Baric
Journal:  mBio       Date:  2013-08-06       Impact factor: 7.867

5.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

  5 in total
  15 in total

Review 1.  COVID-19 and coagulopathy.

Authors:  Malay Sarkar; Irappa V Madabhavi; Pham Nguyen Quy; Manjunath B Govindagoudar
Journal:  Clin Respir J       Date:  2021-08-30       Impact factor: 1.761

Review 2.  COVID-19-associated coagulopathy and disseminated intravascular coagulation.

Authors:  Hidesaku Asakura; Haruhiko Ogawa
Journal:  Int J Hematol       Date:  2020-11-07       Impact factor: 2.490

Review 3.  COVID-19 versus HIT hypercoagulability.

Authors:  Theodore E Warkentin; Scott Kaatz
Journal:  Thromb Res       Date:  2020-08-10       Impact factor: 3.944

4.  Hypercoagulation Detected by Rotational Thromboelastometry Predicts Mortality in COVID-19: A Risk Model Based on a Prospective Observational Study.

Authors:  Lou M Almskog; Agneta Wikman; Jonas Svensson; Matteo Bottai; Mariann Kotormán; Carl-Magnus Wahlgren; Michael Wanecek; Jan van der Linden; Anna Ågren
Journal:  TH Open       Date:  2021-12-21

Review 5.  Questions about COVID-19 associated coagulopathy: possible answers from the viscoelastic tests.

Authors:  Vittorio Pavoni; Lara Gianesello; Maddalena Pazzi; Pietro Dattolo; Domenico Prisco
Journal:  J Clin Monit Comput       Date:  2021-07-15       Impact factor: 1.977

6.  In vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVID-19 patients on anticoagulation.

Authors:  Annabel Blasi; Fien A von Meijenfeldt; Jelle Adelmeijer; Andrea Calvo; Cristina Ibañez; Juan Perdomo; Juan C Reverter; Ton Lisman
Journal:  J Thromb Haemost       Date:  2020-09-01       Impact factor: 16.036

7.  Harmonized D-dimer levels upon admission for prognosis of COVID-19 severity: Results from a Spanish multicenter registry (BIOCOVID-Spain study).

Authors:  Luis García de Guadiana-Romualdo; Daniel Morell-García; Emmanuel J Favaloro; Juan A Vílchez; Josep M Bauça; María J Alcaide Martín; Irene Gutiérrez Garcia; Patricia de la Hera Cagigal; José Manuel Egea-Caparrós; Sonia Pérez Sanmartín; José I Gutiérrez Revilla; Eloísa Urrechaga; Jose M Álamo; Ana M Hernando Holgado; María-Carmen Lorenzo-Lozano; Magdalena Canalda Campás; María A Juncos Tobarra; Cristian Morales-Indiano; Isabel Vírseda Chamorro; Yolanda Pastor Murcia; Laura Sahuquillo Frías; Laura Altimira Queral; Elisa Nuez-Zaragoza; Juan Adell Ruiz de León; Alicia Ruiz Ripa; Paloma Salas Gómez-Pablos; Iria Cebreiros López; Amaia Fernández Uriarte; Alex Larruzea; María L López Yepes; Natalia Sancho-Rodríguez; María C Zamorano Andrés; José Pedregosa Díaz; Luis Sáenz; Clara Esparza Del Valle; María C Baamonde Calzada; Sara García Muñoz; Marina Vera; Esther Martín Torres; Silvia Sánchez Fdez-Pacheco; Luis Vicente Gutiérrez; Laura Jiménez Añón; Alfonso Pérez Martínez; Aurelio Pons Castillo; Ruth González Tamayo; Jorge Férriz Vivancos; Olaia Rodríguez-Fraga; Vicens Díaz-Brito; Vicente Aguadero; M G García Arévalo; María Arnaldos Carrillo; Mercedes González Morales; María Núñez Gárate; Cristina Ruiz Iruela; Patricia Esteban Torrella; Martí Vila Pérez; Cristina Acevedo Alcaraz; Alfonso L Blázquez-Manzanera; Amparo Galán Ortega
Journal:  J Thromb Thrombolysis       Date:  2021-07-16       Impact factor: 2.300

Review 8.  Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19.

Authors:  Paul P Dobesh; Toby C Trujillo
Journal:  Pharmacotherapy       Date:  2020-11-03       Impact factor: 6.251

9.  Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (COVID-19).

Authors:  Hanny Al-Samkari; Fei Song; Elizabeth M Van Cott; David J Kuter; Rachel Rosovsky
Journal:  Am J Hematol       Date:  2020-09-02       Impact factor: 13.265

Review 10.  Pathomechanisms Underlying Hypoxemia in Two COVID-19-Associated Acute Respiratory Distress Syndrome Phenotypes: Insights From Thrombosis and Hemostasis.

Authors:  Satoshi Gando; Takeshi Wada
Journal:  Shock       Date:  2022-01-01       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.